Naslov
Early diagnosis of Alzheimer's disease by combination of cerebrospinal fluid core biomarkers and visinin-like protein-1 (VILIP-1)

Autori
Šimić, Goran ; Babić, Mirjana ; Bažadona, Danira ; Borovečki, Fran ; Čerimagić, Denis ; Dejanović, Nenad ; Hajnšek, Sanja ; Henigsberg, Neven ; Jazvinšćak-Jembrek, Maja ; Jovanov- Milošević, Nataša ; Kalanj-Bognar, Svjetlana ; Kiđemet-Piskaš, Spomenka ; Mustapić, Maja ; Mimica, Ninoslav ; Muck-Šeler, Dorotea ; Nedić- Erjavec, Gordana ; Nikolac-Perković, Matea ; Petrović, Ratimir ; Pivac, Nela ; Presečki, Paola ; Radoš, Milan ; Stanić, Gabrijela ; Švob Štrac, Dubravka ; Vogrinc, Željka ; Vukelić, Željka ; Hof, Patrick R.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
The 2014 Alzheimer's disease congress / The 2014 Alzheimer's disease congress - London : Delhi : Euroscicon Ltd UK, 2014, 8-9

Skup
The 2014 Alzheimer's disease congress

Mjesto i datum
London, Ujedinjeno Kraljevstvo, 23.06.2014. - 25.06.2014

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Visinin-like protein-1; Alzheimer's disease; mild cognitive impairment
(Visinin-like protein-1; Alzheimer's disease; mild cognitive impairmen)

Sažetak
Mild cognitive impairment (MCI) is a syndrome characterized by cognitive impairment without dementia, which primarily affects episodic memory. Patients with MCI often have an initial stage of Alzheimer's disease (AD). In this study we compared the effectiveness of 6 CSF biomarkers (Aβ1-42, total tau, p-tau 181, p-tau 199, p-tau 231 and VILIP-1) in differentiation of AD patients from healthy controls (HC). Biomarker levels among AD, MCI, and HC, were compared using the Kruskal- Wallis test (Aβ1- 42: (χ2=10.763 ; df=2 ; p=0.005) ; total tau: (χ2=34.182 ; df=2 ; p<0.001) ; p-tau 181: (χ2=28.329 ; df=2 ; p<0.001) ; p-tau 231: (χ2=28.215 ; df=2 ; p<0.001) ; p-tau 199: (χ2=24.101 ; df=2 ; p<0.001) ; VILIP-1: (χ2=15.588 ; df=2 ; p<0.001)), followed by the Mann-Whitney U test for pairwise comparisons (Aβ1-42: AD vs MCI (U=1032 ; Z=-3.366 ; p=0.001) ; AD vs HC (U=823.5 ; Z=-0.860 ; p=0.390) ; MCI vs HC (U=347.5 ; Z=-1.224 ; p=0.221) ; total tau: AD vs MCI (U=1110 ; Z=-4.786 ; p<0.001) ; AD vs HC (U=428.5 ; Z=-4.336 ; p<0.001) ; MCI vs HC (U=391 ; Z=-1.508 ; p=0.132) ; p-tau 231: AD vs MCI (U=183 ; Z=-3.712 ; p<0.001) ; AD vs HC (U=48 ; Z=-4.816 ; p<0.001) ; MCI vs HC (U=141.5 ; Z=-1.820 ; p=0.069) ; p-tau 181: AD vs MCI (U=878 ; Z=-2.892 ; p=0.004) ; AD vs HC (U=200 ; Z=-4.793 ; p<0.001) ; MCI vs HC (U=152 ; Z=-3.363 ; p=0.001) ; p- tau 199: AD vs MCI (U=197.5 ; Z=-3.861 ; p<0.001) ; AD vs HC (U=69 ; Z=-4.160 ; p<0.001) ; MCI vs HC (U=158.5 ; Z=-0.990 ; p=0.322) ; VILIP-1: AD vs MCI (U=831 ; Z=-3.295 ; p=0.001) ; AD vs HC (U=300.5 ; Z=-2.931 ; p=0.003) ; MCI vs HC (U=279.5 ; Z=-0.467 ; p=0.641). Phospho-tau biomarkers, especially p-tau 199, reached the highest specificity, sensitivity and area under curve (AUC), as revealed by ROC analysis. MCI patients with a high risk of AD development were detected based on cut-off levels for p-tau biomarkers. Five MCI patients (21, 8%) had increased both p-tau 199 and p-tau 181, while 8 MCI patients (34, 8 %) had increased p-tau 199 only. Additionally, 5 MCI patients also had increased both p-tau 199 and p-tau 231. These 5 MCI will be further monitored as they are at risk of AD development. VILIP-1 is not as reliable as phospho-tau biomarkers, but adds to the overall specificity, sensitivity and AUC in differentiating AD from MCI and HC

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Psihologija

POVEZANOST RADA